Found: 124
Select item for more details and to access through your institution.
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1005, doi. 10.1002/ajh.26595
- By:
- Publication type:
- Article
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 914, doi. 10.1002/ajh.26206
- By:
- Publication type:
- Article
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1288, doi. 10.1002/ajh.25939
- By:
- Publication type:
- Article
Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 7, p. 734, doi. 10.1002/ajh.25784
- By:
- Publication type:
- Article
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. 1353, doi. 10.1002/ajh.25638
- By:
- Publication type:
- Article
Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 5, p. 554, doi. 10.1002/ajh.25436
- By:
- Publication type:
- Article
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 4, p. E90, doi. 10.1002/ajh.25387
- By:
- Publication type:
- Article
Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1402, doi. 10.1002/ajh.25259
- By:
- Publication type:
- Article
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1318, doi. 10.1002/ajh.25243
- By:
- Publication type:
- Article
Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 9, p. 1136, doi. 10.1002/ajh.25198
- By:
- Publication type:
- Article
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. 91, doi. 10.1002/ajh.24947
- By:
- Publication type:
- Article
CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 10, p. 1113, doi. 10.1002/ajh.24841
- By:
- Publication type:
- Article
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 1, p. 7, doi. 10.1002/ajh.24568
- By:
- Publication type:
- Article
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 11, p. E478, doi. 10.1002/ajh.24496
- By:
- Publication type:
- Article
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, p. 385, doi. 10.1002/ajh.24296
- By:
- Publication type:
- Article
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 4, p. 385, doi. 10.1002/ajh.24296
- By:
- Publication type:
- Article
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 6, p. 471, doi. 10.1002/ajh.23978
- By:
- Publication type:
- Article
Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 3, p. 282, doi. 10.1002/ajh.23624
- By:
- Publication type:
- Article
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 12, p. 1024, doi. 10.1002/ajh.23560
- By:
- Publication type:
- Article
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-02329-y
- By:
- Publication type:
- Article
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
- Published in:
- Nature Communications, 2016, v. 7, n. 5, p. 11589, doi. 10.1038/ncomms11589
- By:
- Publication type:
- Article
Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 6, p. 5481, doi. 10.3390/ijms24065481
- By:
- Publication type:
- Article
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 6, p. 5460, doi. 10.3390/ijms24065460
- By:
- Publication type:
- Article
The cXcr4-sTaT3-il-10 Pathway controls the immunoregulatory Function of chronic lymphocytic leukemia and is Modulated by lenalidomide.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2017.01773
- By:
- Publication type:
- Article
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
- Published in:
- Oncogene, 2005, v. 24, n. 27, p. 4462, doi. 10.1038/sj.onc.1208621
- By:
- Publication type:
- Article
KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway.
- Published in:
- Oncogene, 2005, v. 24, n. 12, p. 2067, doi. 10.1038/sj.onc.1208442
- By:
- Publication type:
- Article
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
- Published in:
- Oncogene, 2003, v. 22, n. 50, p. 8093, doi. 10.1038/sj.onc.1207097
- By:
- Publication type:
- Article
CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S322, doi. 10.1016/S2152-2650(21)01759-6
- By:
- Publication type:
- Article
CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S316, doi. 10.1016/S2152-2650(21)01747-X
- By:
- Publication type:
- Article
Poster: CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S222, doi. 10.1016/S2152-2650(21)01401-4
- By:
- Publication type:
- Article
Poster: CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01393-8
- By:
- Publication type:
- Article
P300 Induces STAT3 Acetylation and Provides CLL Cells with Survival Advantage.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S277, doi. 10.1016/j.clml.2019.07.210
- By:
- Publication type:
- Article
Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S274, doi. 10.1016/j.clml.2019.07.205
- By:
- Publication type:
- Article
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S13, doi. 10.1016/j.clml.2017.09.041
- By:
- Publication type:
- Article
Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S12, doi. 10.1016/j.clml.2017.09.040
- By:
- Publication type:
- Article
CLL and Fat Cells Utilize Similar Metabolic Pathways.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S303, doi. 10.1016/j.clml.2017.07.099
- By:
- Publication type:
- Article
Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S304, doi. 10.1016/j.clml.2017.07.100
- By:
- Publication type:
- Article
Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S299, doi. 10.1016/j.clml.2017.07.094
- By:
- Publication type:
- Article
Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S265, doi. 10.1016/j.clml.2017.07.033
- By:
- Publication type:
- Article
Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S45, doi. 10.1016/j.clml.2016.07.065
- By:
- Publication type:
- Article
Stimulation of the B-Cell Receptor (BCR) Induces Tyrosine Phosphorylation of STAT3 via NF-κB Dependent Mechanism.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S40, doi. 10.1016/j.clml.2016.07.057
- By:
- Publication type:
- Article
Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S43, doi. 10.1016/j.clml.2016.07.062
- By:
- Publication type:
- Article
Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S41, doi. 10.1016/j.clml.2016.07.059
- By:
- Publication type:
- Article
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
- Published in:
- 2014
- By:
- Publication type:
- journal article
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
- Published in:
- 2013
- By:
- Publication type:
- journal article